Adaptive Biotechnologies Q4 revenue +26% to $37.9M; CFO Chad Cohen resigns, interim CFO appointed

Adaptive Biotechnologies Corp

2022-FY EPS reported -$1.48 revenue$154,344,000

Q4 2021 revenue $37.9M (+26% YoY); net loss $61.4M (vs $44.6M). Full year revenue $154.3M (+57%); net loss $207.3M.
Sequencing revenue Q4 $23.1M (+81% YoY); clonoSEQ clinical tests Q4 6,356 (+41%), full year 22,516 (+48%).
Development revenue Q4 $14.9M (-15% YoY); cash, equivalents and marketable securities $570.2M at Dec 31, 2021.
CFO Chad Cohen resigned effective Feb 15, 2022; Kyle Piskel appointed interim CFO.
Genentech selected TCR candidate targeting shared cancer neoantigen; T-Detect COVID EUA with over 30,000 tests ordered.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Kyle Piskel

Interim Chief Financial Officer

ADPT · Adaptive Biotechnologies Corp

Effective: 2022-02-15
Filed: February 15, 2022, 6:59 PM ET

the Board of Directors of the Company appointed Mr. Kyle Piskel, the Company’s Principal Accounting Officer, as interim Chief Financial Officer effective concurrent with Mr. Cohen’s resignation

Departed

Chad Cohen

Chief Financial Officer

ADPT · Adaptive Biotechnologies Corp

Effective: 2022-02-15
Successor: Kyle Piskel
Filed: February 15, 2022, 6:59 PM ET

the Company’s Chief Financial Officer, Mr. Chad Cohen, is resigning effective February 15, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Kyle Piskel was appointed as Interim Chief Financial Officer at Adaptive Biotechnologies Corp.

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

the Board of Directors of the Company appointed Mr. Kyle Piskel, the Company’s Principal Accounting Officer, as interim Chief Financial Officer effective concurrent with Mr. Cohen’s resignation

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Chad Cohen resigned as Chief Financial Officer at Adaptive Biotechnologies Corp.

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

the Company’s Chief Financial Officer, Mr. Chad Cohen, is resigning effective February 15, 2022

View on SEC.gov

Adaptive Biotechnologies Corp filing history →

Source: SEC EDGAR

accession 0001564590-22-005219

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.